Failed ALS Drug BIIB078 Reached Target but Failed to Halt Disease Progression, Emory Study Reveals
核心洞察
Emory University researchers analyzed why BIIB078, an antisense oligonucleotide therapy for genetic ALS (搜索), failed despite successfully reaching its target in the central nervous system and reducing some toxic proteins.
The study examined samples from eight C9orf72-linked ALS (搜索) patients who received BIIB078 and found the drug spread widely throughout the brain and spinal cord but did not improve key disease processes or halt abnormal protein buildup.
Researchers discovered significant variability in patient responses to the therapy and concluded that cerebrospinal fluid biomarkers do not always reflect actual changes in central nervous system tissue.
A comprehensive analysis by Emory University researchers has revealed why BIIB078, a once-promising experimental therapy for amyotrophic lateral sclerosis (搜索) (ALS (搜索)), failed to help patients despite successfully reaching its intended target in the central nervous system. The findings, published in Cell, provide crucial insights into the challenges of developing effective treatments for this devastating neurodegenerative disease.
Drug Successfully Penetrated Brain Tissue but Failed to Halt Disease
BIIB078, an antisense oligonucleotide (ASO) developed to treat genetic ALS (搜索) linked to C9orf72 mutations, was designed as a short strand of synthetic genetic material to block the production of toxic RNA and proteins. The C9orf72 genetic mutation represents the most common inherited cause of ALS, a progressive condition that attacks nerve cells controlling muscle movement.
The clinical trial of BIIB078 was halted in 2021 after patients showed no clinical improvement, despite cerebrospinal fluid biomarkers suggesting the drug was hitting its intended target. "Disease-specific biomarkers in the cerebrospinal fluid (CSF) suggested that the ASO was hitting its intended target, but it was not clear if it penetrated CNS tissue and affected the disease itself," explained Zachary McEachin, PhD, assistant professor of Human Genetics at Emory University and lead author of the study.
Comprehensive Analysis Reveals Drug Distribution and Limitations
The research team conducted a detailed analysis of samples from trial participants, examining cerebrospinal fluid collected during life along with postmortem brain and spinal cord tissue. The study included eight individuals with C9orf72-linked ALS (搜索) who received BIIB078 and 31 ALS patients who did not receive the drug.
The analysis revealed that BIIB078 spread widely throughout the central nervous system and successfully reduced some of the toxic proteins linked to ALS (搜索). However, the drug failed to improve or reverse the key disease processes that drive ALS progression, particularly the buildup of abnormal brain proteins.
"Getting the drug to the CNS is only part of the challenge. We need better ways to know whether a treatment is truly changing the course of ALS (搜索). Our study addresses some of those questions and shows that CSF biomarkers do not always reflect changes in the CNS," McEachin noted.
Patient Variability Highlights Need for Personalized Approaches
The study uncovered significant variability among patients in their biological responses to the ASO treatment, demonstrating the complexity of therapeutic interventions in ALS (搜索). This variability underscores the importance of understanding individual patient responses, a critical consideration for precision and personalized medicine approaches.
"This work utilized integrated proteomic approaches to rigorously evaluate molecular changes in both tissue and CSF following ASO therapy, providing new biomarkers of treatment and insights to better design and monitor future clinical trials," said Nicholas Seyfried, PhD, professor of Biochemistry and co-senior author.
Implications for Future ASO Therapies
The research has significant implications for the broader field of antisense oligonucleotide therapies, several of which are currently in clinical use or under investigation. "Several ASO therapies are either now in clinical use or in trial. We expect our new data will be influential in the development of new ASO-directed therapies," stated Jonathan Glass, MD, director of the Emory ALS Center (搜索) and professor in the Department of Neurology.
The findings emphasize the urgent need for improved biomarkers that can demonstrate in real time whether experimental therapies are meaningfully impacting ALS (搜索) disease progression. Most people with ALS live only two to five years after diagnosis, and effective treatments remain severely limited.
Research Context and Future Directions
ALS (搜索) affects neurons in the spinal cord that control movement, causing them to gradually die off and resulting in progressive loss of function that can be fatal within five years of diagnosis, though some patients live much longer. While the majority of ALS cases are sporadic, this study focused specifically on the genetic form linked to C9orf72 mutations, which accounts for approximately 10% of all cases.
The research represents an important step forward in understanding the biology of ASO therapies in neurological diseases and highlights the complex challenges involved in translating promising preclinical results into effective treatments for patients with neurodegenerative conditions.